POST-TEST

A Conversation with the Investigators: Chimeric Antigen Receptor T-Cell Therapy in Hematologic Cancers (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **What was reported regarding overall and complete response rates with the FDA-approved chimeric antigen receptor (CAR) T-cell therapeutic agent brexucabtagene autoleucel for patients with relapsed/refractory (R/R) mantle cell lymphoma on the Phase II ZUMA-2 trial?**
   a. High overall response rate with more than 50% complete responses
   b. 50% overall response rate but no complete responses
   c. Low overall response rate with no complete responses

2. **Based on the results of the Phase II KarMMa trial, the CAR T-cell therapy idecabtagene vicleucel (ide-cel) recently received FDA approval for the treatment of R/R multiple myeloma (MM) after at least 4 prior lines of therapy. What is the target of ide-cel?**
   a. CD19
   b. BCMA
   c. CD20

3. **Updated results presented at ASCO 2021 from the CARTITUDE-1 study of ciltacabtagene autoleucel for patients with R/R MM included which of the following outcomes?**
   a. High overall response rate (>80%) only
   b. High minimal residual disease (MRD) negativity rate (>80%) only
   c. Both high overall response rate (>80%) and high MRD negativity rate (>80%)

4. **Which of the following CAR T-cell products is being compared to standard second-line therapy in the ongoing Phase III BELINDA trial for patients with R/R aggressive B-cell non-Hodgkin lymphoma?**
   a. Lisocabtagene maraleucel
   b. Tisagenlecleucel
   c. Axicabtagene ciloleucel
   d. Idecabtagene vicleucel
   e. Ciltacabtagene autoleucel

5. **On the basis of the results of the ZUMA-5 trial, axicabtagene ciloleucel is FDA approved for which patients with follicular lymphoma?**
   a. Patients with R/R disease after 2 or more lines of therapy
   b. Patients with R/R disease after 1 line of therapy
   c. Patients with newly diagnosed disease